Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024;20(4):e070823219470.
doi: 10.2174/1573399820666230807145202.

Influence of Solute Carrier Family 22 Member 1 (SLC22A1) Gene Polymorphism on Metformin Pharmacokinetics and HbA1c Levels: A Systematic Review

A D Pradana  1   2 , E Kristin  2 , D A A Nugrahaningsih  2 , A K Nugroho  3 , R T Pinzon  4
Affiliations

Influence of Solute Carrier Family 22 Member 1 (SLC22A1) Gene Polymorphism on Metformin Pharmacokinetics and HbA1c Levels: A Systematic Review

A D Pradana et al. Curr Diabetes Rev. 2024.

Abstract

Background: Solute Carrier Family 22 Member 1 (SLC22A1, also known as OCT1) protein has a vital role in the metabolism of metformin, a first-line anti-diabetes medication. Genetic poly-morphism in SLC22A1 influences individual response to metformin.

Objective: This review aims to compile the current knowledge about the effects of SLC22A1 genetic polymorphism on metformin pharmacokinetics and HbA1c levels.

Methods: We followed the PRISMA 2020 standards to conduct a systematic review. We searched the publications for all appropriate evidence on the effects of SLC22A1 genetic polymorphism on metformin pharmacokinetics and HbA1c from January 2002 to December 2022.

Results: Initial database searches identified 7,171 relevant studies. We reviewed 155 titles and abstracts after deleting duplicates. After applying inclusion and exclusion criteria, 23 studies remained.

Conclusion: Three studies found that rs12208357, rs34059508, and G465R had a considerable impact (p < 0.05) on metformin pharmacokinetics, resulting in increased metformin plasma (Cmax), a higher active amount of drug in the blood (AUC), and lower volume of distribution (Vd) (p<0.05). SLC22A1 polymorphisms with effects on HbA1c include rs628031 (four of seven studies), rs622342 (four of six studies), rs594709 (one study), rs2297374, and rs1867351 (one of two studies), rs34130495 (one study), and rs11212617 (one study) (p < 0.05).

Keywords: HbA1c; OCT1; metformin; pharmacokinetics; polymorphisms; type 2 diabetes..

PubMed Disclaimer

References

    1. Inzucchi S.E.; Bergenstal R.M.; Buse J.B.; Management of hyperglycaemia in type 2 diabetes, 2015: A patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the study of diabetes. Diabetologia 2015,58(3),429-442 - DOI - PubMed
    1. Nathan D.M.; Buse J.B.; Davidson M.B.; Medical management of hyperglycaemia in type 2 diabetes mellitus: A consensus algorithm for the initiation and adjustment of therapy. Diabetologia 2009,52(1),17-30 - DOI - PubMed
    1. Rodbard H.W.; Jellinger P.S.; Davidson J.A.; Statement by an American association of clinical endocrinologists/American college of endocrinology consensus panel on type 2 diabetes mellitus: An algorithm for glycemic control. Endocr Pract 2009,15(6),540-559 - DOI - PubMed
    1. Flory J.; Lipska K.; Metformin in 2019. JAMA 2019,321(19),1926-1927 - DOI - PubMed
    1. Hostalek U.; Gwilt M.; Hildemann S.; Therapeutic use of metformin in prediabetes and diabetes prevention. Drugs 2015,75(10),1071-1094 - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources